TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Monte Rosa Therapeutics
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

Monte Rosa Therapeutics presented preclinical data on MRT-8102, a molecular glue degrader targeting NEK7, which shows potential in treating cardiovascular and cardiometabolic diseases by modulating the NLRP3 inflammasome pathway.

Insights
TGT   neutral

Mentioned as a platform for wishlist donations, with no significant positive or negative context


GLUE   positive

Company presented promising preclinical data demonstrating potential breakthrough in treating inflammatory diseases, with initial Phase 1 study on track and unique approach to targeting cardiovascular inflammation